How much is the candida infection testing market worth, and how is it expected to expand?
The candida infection testing market size has grown strongly in recent years. It will grow from $15.69 $ billion in 2024 to $16.72 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to the rising incidence of candida infections, growing awareness and diagnostics, expansion of healthcare infrastructure, rise in hospital-acquired infections, and increasing funding for research.
The candida infection testing market size is expected to see strong growth in the next few years. It will grow to $21.29 $ billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to the emergence of new candida strains, rising awareness of fungal infections, expansion of healthcare access, aging population, rising awareness and preventive healthcare. Major trends in the forecast period include advancements in molecular diagnostics, integration of digital health technologies, integration of AI, integration of machine learning, and personalized medicine.
Get Your Free Sample of The Global Candida Infection Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19356&type=smp
Which industry factors have accelerated the candida infection testing market’s expansion?
The increasing incidence of yeast infections is expected to propel the growth of the candida infection testing market going forward. Yeast infections refer to fungal infections caused by the overgrowth of candida, commonly affecting areas such as the mouth, genitals, and skin, and often resulting in itching, redness, and discomfort. Yeast infections are primarily caused by an overgrowth of the fungus candida, often due to imbalances in the body’s natural bacteria, weakened immune systems, or hormonal changes. Candida infection testing is used in yeast infections to accurately diagnose the presence of candida overgrowth, helping healthcare providers confirm the infection and guide appropriate treatment. For instance, in September 2023, according to GOV.UK, a UK-based government agency, in 2022, the rate of bloodstream infections (BSI) caused by yeast in England was 4.0 per 100,000 population, marking a 4% increase compared to 2021. Therefore, the increasing incidence of yeast infections will drive the growth of the candida infection testing market.
What are the primary segments of the candida infection testing market?
The candida infection testingmarket covered in this report is segmented –
1) By Type: Invasive Candidiasis, Candidemia
2) By Test Type: Vaginal pH Test, Nucleic Acid Amplification Testing (NAAT), Microbiome Test
3) By Application: Hospital, Laboratory
Subsegments:
1) By Invasive Candidiasis: Tissue Biopsy Testing, Urine Culture Testing, Blood Culture Testing
2) By Candidemia: Blood Tests, Serological Testing, Molecular Testing
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/candida-infection-testing-global-market-report
Which firms are leading the candida infection testing market?
Major companies operating in the candida infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, Siemens Healthineers AG, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Cepheid, Randox Laboratories Ltd., Meridian Bioscience Inc., DiaSorin S.p.A., Sekisui Diagnostics LLC, Enzo Biochem Inc., T2 Biosystems Inc., Aidian Oy, SafeCare LLC, CHROMagar, HK Biotek Inc., Health Testing Centers LLC, Accesa Labs LLC, Private MD Labs LLC
Which market trends are set to define the future of the candida infection testing market?
Major companies operating in the candida infection testing market are focusing on developing technologically innovative solutions, such as a fully automated PCR rapid test for detecting candida, to enhance diagnostic accuracy and improve patient outcomes. A fully automated PCR rapid test for detecting candida refers to a high-tech diagnostic tool that uses polymerase chain reaction (PCR) technology to quickly and accurately identify the presence of Candida species in clinical samples. For instance, in May 2024, Bosch Healthcare Solutions GmbH, a Germany-based medical technology manufacturer, launched a PCR test for candida auris detection on the Vivalytic platform, offering fully automated, rapid testing within an hour at the point of care. This advanced test allows for prompt screenings and contrasts sharply with traditional culture methods, which take one to three days in centralized labs, thus delaying diagnosis and treatment. Designed for clinical settings, the test is particularly beneficial for high-risk patients, enabling timely diagnosis and treatment to combat the serious health risks associated with C. auris infections.
Which geographic trends are shaping the candida infection testing market, and which region has the highest market share?
North America was the largest region in the candida infection testing market in 2024. The regions covered in the candida infection testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Candida Infection Testing Market Report 2025 Offer?
The candida infection testing market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Candida infection testing refers to diagnostic procedures used to identify the presence of candida species, which are fungi that can cause infections in various parts of the body. These tests help determine the type and extent of the Candida infection, guiding appropriate treatment strategies.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19356
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
